PostEra inks AI research collaboration with Amgen

Boston, USA-based biotechnology start-up PostEra, which specializes in artificial intelligence for pre-clinical drug discovery, has entered into a multi-target collaboration with US biotech major Amgen (Nasdaq: AMGN).

The collaboration will leverage PostEra's AI platform, Proton, a pioneering innovation in generative chemistry and synthesis-aware design, and Amgen's drug discovery expertise, to advance up to five small molecule programs. Upon a certain number of programs entering the collaboration, Amgen will have the option to access some of PostEra's key AI technologies for its in-house programs, outside of the collaboration.

The agreement includes undisclosed upfront funding, and milestone payments, in addition to royalties on any approved products arising from the collaboration.